BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Broecker-Preuss M, Viehof J, Jastrow H, Becher-Boveleth N, Fuhrer D, Mann K. Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer Res 2015;34:69. [PMID: 26198850 DOI: 10.1186/s13046-015-0186-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Tan YQ, Zhang X, Zhang S, Zhu T, Garg M, Lobie PE, Pandey V. Mitochondria: The metabolic switch of cellular oncogenic transformation. Biochim Biophys Acta Rev Cancer 2021;1876:188534. [PMID: 33794332 DOI: 10.1016/j.bbcan.2021.188534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Opydo-Chanek M, Cichoń I, Rak A, Kołaczkowska E, Mazur L. The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells. Invest New Drugs 2020;38:1664-76. [PMID: 32367199 DOI: 10.1007/s10637-020-00931-4] [Reference Citation Analysis]
3 Xiang Y, Zhao J, Zhao M, Wang K. Allicin activates autophagic cell death to alleviate the malignant development of thyroid cancer. Exp Ther Med 2018;15:3537-43. [PMID: 29545880 DOI: 10.3892/etm.2018.5828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
4 Champa D, Orlacchio A, Patel B, Ranieri M, Shemetov AA, Verkhusha VV, Cuervo AM, Di Cristofano A. Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget 2016;7:34453-71. [PMID: 27144341 DOI: 10.18632/oncotarget.9121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
5 Cui Q, Wen S, Huang P. Targeting cancer cell mitochondria as a therapeutic approach: recent updates. Future Medicinal Chemistry 2017;9:929-49. [DOI: 10.4155/fmc-2017-0011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
6 Opydo-Chanek M, Gonzalo O, Marzo I. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects. Biochem Pharmacol 2017;136:12-23. [PMID: 28288819 DOI: 10.1016/j.bcp.2017.03.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
7 Gao C, Sun R, Xie YR, Jiang AL, Lin M, Li M, Chen ZW, Zhang P, Jin H, Feng JP. The soy-derived peptide Vglycin inhibits the growth of colon cancer cells in vitro and in vivo. Exp Biol Med (Maywood) 2017;242:1034-43. [PMID: 28492347 DOI: 10.1177/1535370217697383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Broecker-Preuss M, Becher-Boveleth N, Müller S, Mann K. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells. Cancer Cell Int 2016;16:27. [PMID: 27042160 DOI: 10.1186/s12935-016-0303-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
9 Thomas MG, Marwood RM, Parsons AE, Parsons RB. The effect of foetal bovine serum supplementation upon the lactate dehydrogenase cytotoxicity assay: Important considerations for in vitro toxicity analysis. Toxicol In Vitro 2015;30:300-8. [PMID: 26498060 DOI: 10.1016/j.tiv.2015.10.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W, Cao Y, Zhao S, Zhang W, Qiu Z, Liu D, Mo X, Li W. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer. J Exp Clin Cancer Res 2015;34:126. [PMID: 26490682 DOI: 10.1186/s13046-015-0239-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]